COVID-19 UPDATE

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

News Releases

News Releases

Date
Title
Document
August 4, 2021
BioDelivery Sciences Reports Second Quarter 2021 Results
PDF Version
August 4, 2021
BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine
PDF Version
July 22, 2021
BioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021
PDF Version
May 6, 2021
BioDelivery Sciences Reports First Quarter 2021 Results
PDF Version
April 20, 2021
BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021
PDF Version
March 10, 2021
BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results
PDF Version
February 17, 2021
BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021
PDF Version
February 11, 2021
BioDelivery Sciences CFO Terry Coelho Promoted to Executive Vice President
PDF Version
January 15, 2021
BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS) Meeting
PDF Version
November 20, 2020
BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference
PDF Version

Investor Presentation

More information is coming soon.


Upcoming Events

More events are coming soon.

Stay Connected

Stay up to date on the latest news

Get started now
July 9, 2021 /
Data provided by West LLC. Minimum 15 minutes delayed.